Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros












Intervalo de año de publicación
1.
Int J Equity Health ; 23(1): 161, 2024 Aug 15.
Artículo en Inglés | MEDLINE | ID: mdl-39148041

RESUMEN

In this study, we evaluated and forecasted the cumulative opportunities for residents to access radiotherapy services in Cali, Colombia, while accounting for traffic congestion, using a new people-centred methodology with an equity focus. Furthermore, we identified 1-2 optimal locations where new services would maximise accessibility. We utilised open data and publicly available big data. Cali is one of South America's cities most impacted by traffic congestion. METHODOLOGY: Using a people-centred approach, we tested a web-based digital platform developed through an iterative participatory design. The platform integrates open data, including the location of radiotherapy services, the disaggregated sociodemographic microdata for the population and places of residence, and big data for travel times from Google Distance Matrix API. We used genetic algorithms to identify optimal locations for new services. We predicted accessibility cumulative opportunities (ACO) for traffic ranging from peak congestion to free-flow conditions with hourly assessments for 6-12 July 2020 and 23-29 November 2020. The interactive digital platform is openly available. PRIMARY AND SECONDARY OUTCOMES: We present descriptive statistics and population distribution heatmaps based on 20-min accessibility cumulative opportunities (ACO) isochrones for car journeys. There is no set national or international standard for these travel time thresholds. Most key informants found the 20-min threshold reasonable. These isochrones connect the population-weighted centroid of the traffic analysis zone at the place of residence to the corresponding zone of the radiotherapy service with the shortest travel time under varying traffic conditions ranging from free-flow to peak-traffic congestion levels. Additionally, we conducted a time-series bivariate analysis to assess geographical accessibility based on economic stratum. We identify 1-2 optimal locations where new services would maximize the 20-min ACO during peak-traffic congestion. RESULTS: Traffic congestion significantly diminished accessibility to radiotherapy services, particularly affecting vulnerable populations. For instance, urban 20-min ACO by car dropped from 91% of Cali's urban population within a 20-min journey to the service during free-flow traffic to 31% during peak traffic for the week of 6-12 July 2020. Percentages represent the population within a 20-min journey by car from their residence to a radiotherapy service. Specific ethnic groups, individuals with lower educational attainment, and residents on the outskirts of Cali experienced disproportionate effects, with accessibility decreasing to 11% during peak traffic compared to 81% during free-flow traffic for low-income households. We predict that strategically adding sufficient services in 1-2 locations in eastern Cali would notably enhance accessibility and reduce inequities. The recommended locations for new services remained consistent in both of our measurements.These findings underscore the significance of prioritising equity and comprehensive care in healthcare accessibility. They also offer a practical approach to optimising service locations to mitigate disparities. Expanding this approach to encompass other transportation modes, services, and cities, or updating measurements, is feasible and affordable. The new approach and data are particularly relevant for planning authorities and urban development actors.


Asunto(s)
Accesibilidad a los Servicios de Salud , Radioterapia , Viaje , Humanos , Colombia , Accesibilidad a los Servicios de Salud/estadística & datos numéricos , Estudios Transversales , Viaje/estadística & datos numéricos , Radioterapia/estadística & datos numéricos , Radioterapia/normas , Macrodatos
2.
JCO Glob Oncol ; 10: e2300256, 2024 May.
Artículo en Inglés | MEDLINE | ID: mdl-38781548

RESUMEN

PURPOSE: There is an urgent need to improve access to cancer therapy globally. Several independent initiatives have been undertaken to improve access to cancer medicines, and additional new initiatives are in development. Improved sharing of experiences and increased collaboration are needed to achieve substantial improvements in global access to essential oncology medicines. METHODS: The inaugural Access to Essential Cancer Medicines Stakeholder Meeting was organized by ASCO and convened at the June 2022 ASCO Annual Meeting in Chicago, IL, with two subsequent meetings, Union for International Cancer Control World Cancer Congress held in Geneva, Switzerland, in October 2022 and at the ASCO Annual Meeting in June of 2023. Invited stakeholders included representatives from cancer institutes, physicians, researchers, professional societies, the pharmaceutical industry, patient advocacy organizations, funders, cancer organizations and foundations, policy makers, and regulatory bodies. The session was moderated by ASCO. Past efforts and current and upcoming initiatives were initially discussed (2022), updates on progress were provided (2023), and broad agreement on resulting action steps was achieved with participants. RESULTS: Summit participants recognized that while much work was ongoing to enhance access to cancer therapeutics globally, communication and synergy across projects and organizations could be enhanced by providing a platform for collaboration and shared expertise. CONCLUSION: The summit resulted in new cross-stakeholder insights and planned collaboration addressing barriers to accessing cancer medications. Specific actions and timelines for implementation and reporting were established.


Asunto(s)
Salud Global , Accesibilidad a los Servicios de Salud , Neoplasias , Humanos , Accesibilidad a los Servicios de Salud/organización & administración , Neoplasias/tratamiento farmacológico , Antineoplásicos/uso terapéutico , Antineoplásicos/provisión & distribución , Participación de los Interesados , Medicamentos Esenciales/provisión & distribución
3.
Rev. chil. anest ; 51(1): 67-74, 2022. ilus, tab
Artículo en Inglés | LILACS | ID: biblio-1567993

RESUMEN

BACKGROUND: Many adjuvants have been studied to improve the quality of analgesia and to prolong its duration. To date, there are no reports on the use of triamcinolone. CASE: We present a brief report of 10 patients receiving a single shot ACB and IPACK blockade with a small dose of triamcinolone for Fast-Track Knee Replacement to prolong analgesia. CONCLUSION: We think this is a valuable opioid-sparing option, cheaper than new adjuvants, and safer than the use of continuous infusion. This technique should be evaluated in clinical trials.


ANTECEDENTES: Muchos agentes farmacológicos que se utilizan como adyuvantes en la anestesia regional han sido estudiados con el fin de mejorar la calidad de la analgesia y prolongar la duración del efecto. Hoy en día no existen reportes del uso de triamcinolona en dichos procedimientos. CASO: Consiste en el reporte breve de 10 pacientes que se les realizo ACB además de un bloqueo IPACK con una sola inyección de anestesia local con el adyuvante triamcinolona, con el objetivo de prolongar la analgesia en la cirugía de reemplazo de rodilla Fast-Track. CONCLUSIÓN: Consideramos que una valiosa opción para el ahorro de opioide, más económica que las nuevas opciones de mercado y más seguras que el uso de infusiones continuas. Esta técnica debería ser evaluada en ensayos clínicos.


Asunto(s)
Humanos , Masculino , Femenino , Anciano , Anciano de 80 o más Años , Triamcinolona/administración & dosificación , Artroplastia de Reemplazo de Rodilla/métodos , Dolor Musculoesquelético/tratamiento farmacológico , Anestesia de Conducción/métodos , Arteria Poplítea , Recuperación de la Función , Manejo del Dolor , Analgésicos/administración & dosificación , Adyuvantes Anestésicos , Bloqueo Nervioso/métodos
4.
JCO Glob Oncol ; 7: 901-916, 2021 06.
Artículo en Inglés | MEDLINE | ID: mdl-34129359

RESUMEN

The effective implementation of locally adapted cancer care solutions in low- and middle-income countries continues to be a challenge in the face of fragmented and inadequately resourced health systems. Consequently, the translation of global cancer care targets to local action for patients has been severely constrained. City Cancer Challenge (C/Can) is leveraging the unique value of cities as enablers in a health systems response to cancer that prioritizes the needs of end users (patients, their caregivers and families, and health care providers). C/Can's City Engagement Process is an implementation framework whereby local stakeholders lead a staged city-wide process over a 2- to 3-year period to assess, plan, and execute locally adapted cancer care solutions. Herein, the development and implementation of the City Engagement Process Framework (CEPF) is presented, specifying the activities, outputs, processes, and indicators across the process life cycle. Lessons learned on the application of the framework in the first so-called Key Learning cities are shared, focusing on the early outputs from Cali, Colombia, the first city to join C/Can in 2017. Creating lasting change requires the creation of a high-trust environment to engage the right stakeholders as well as adapting to local context, leveraging local expertise, and fostering a sustainability mindset from the outset. In the short term, these early learnings inform the refinement of the approach in new cities. Over time, the implementation of this framework is expected to validate the proof-of-concept and contribute to a global evidence base for effective complex interventions to improve cancer care in low- and middle-income countries.


Asunto(s)
Países en Desarrollo , Neoplasias , Ciudades , Colombia , Humanos , Renta , Neoplasias/terapia
5.
Int J Mol Sci ; 20(22)2019 Nov 13.
Artículo en Inglés | MEDLINE | ID: mdl-31766160

RESUMEN

The complex physiology of eukaryotic cells is regulated through numerous mechanisms, including epigenetic changes and posttranslational modifications. The wide-ranging diversity of these mechanisms constitutes a way of dynamic regulation of the functionality of proteins, their activity, and their subcellular localization as well as modulation of the differential expression of genes in response to external and internal stimuli that allow an organism to respond or adapt to accordingly. However, alterations in these mechanisms have been evidenced in several autoimmune diseases, including systemic lupus erythematosus (SLE). The present review aims to provide an approach to the current knowledge of the implications of these mechanisms in SLE pathophysiology.


Asunto(s)
Epigénesis Genética , Lupus Eritematoso Sistémico/genética , Procesamiento Proteico-Postraduccional , Acetilación , Animales , Glicosilación , Humanos , Hidroxilación , Lupus Eritematoso Sistémico/metabolismo , Fosforilación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...